BRM412
Neovascular eye diseases occur when abnormal blood vessels form inside the eye. These vessels are fragile and prone to leakage or bleeding, which can damage the retinal photoreceptors and lead to vision loss or even blindness. Common conditions include wet age-related macular degeneration, choroidal neovascularization associated with high myopia, and diabetic retinopathy.In these conditions, the new blood vessels are often unhealthy, penetrating the retina and causing bleeding or swelling. Common symptoms include blurred vision, distorted images, dark spots or flashes in the visual field, and rapid deterioration of central vision. The primary treatment is intravitreal injection of anti-VEGF drugs, which inhibit abnormal blood vessel growth and reduce leakage. Photodynamic therapy and laser photocoagulation are also used depending on the case. Preventive measures include regular eye examinations, quitting smoking, maintaining a balanced diet with antioxidants, and controlling the progression of myopia to reduce the risk of abnormal blood vessel formation and vision damage.
BRM412 uses coordinated supramolecular complex technology designed by the Industrial Technology Research Institute (ITRI) to develop an eye drop formulation which overcomes the current limitation of intravitreal injection for wet age-related macular degeneration (Wet AMD). By effectively delivering the anti-angiogenic tyrosinase inhibitor (TKI), axitinib, to retina and choroid tissue, BRM412 offers a non-invasive treatment option with better medication compliance that avoids the pain, infection risk, and side effects of injections, such as retinal detachment.
In Phase II clinical trial, BRM412 demonstrated efficacy in inhibiting neovascularization in the majority of patients with nAMD, eliminating the need for intraocular anti-VEGF injections for up to nine months. Recognized for its innovation and technological breakthroughs, BRM412’s core technology was won the Silver Award at the 2023 Edison Awards. As the first non-invasive drop-based therapy against nAMD, BRM412 not only has the potential to replace current intravitreal injections, but also has the possibility to improve treatment compliance and expand the applicable population.
